Offer Booklet for Renounceable Rights Issue
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Cyclopharm
- Technegas COPD Trial Update
- Update on Cyclotron Facility
- Technegas May Facilitate Earlier Diagnosis of COPD
- Technegas Clinical Trial - First Patient Enrolled
- Results of Mediation
Later from Cyclopharm
- Clinical Protocol Approval from US FDA
- Regulatory Approval in China
- Renewal of Debt Facility with National Australia Bank
- Renounceable Rights Issue and Sale of Unmarketable Parcels
- Trading Update
Follow Cyclopharm into a list and get an email when it puts out news.
Follow Cyclopharm